Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 ...
This episode, titled ‘Understanding MG Pathophysiology and Therapeutic Targets,’ features panelists examining how advances in ...
AV-1959R is an investigational amyloid-beta vaccine from Nuravax. The FDA granted it Fast Track designation for preventing Alzheimer disease in cognitively unimpaired people with biomarker evidence of ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
FcRn-targeted therapies share a therapeutic pathway but are not identical. Molecular design, dosing strategy, route of administration, and patient preference can all shape treatment selection. This ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
Please check back later for more content.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results